1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. Summary
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/04/2021 | 02:00am EDT

Ascelia Pharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was SEK 28.52 million compared to SEK 14.69 million a year ago. Basic loss per share from continuing operations was SEK 0.82 compared to SEK 0.51 a year ago. For the nine months, net loss was SEK 90.83 million compared to SEK 62.85 million a year ago. Basic loss per share from continuing operations was SEK 2.8 compared to SEK 2.47 a year ago.


© S&P Capital IQ 2021
All news about ASCELIA PHARMA AB (PUBL)
05/11TRANSCRIPT : Ascelia Pharma AB, Q1 2022 Earnings Call, May 11, 2022
CI
05/11QUARTERLY REPORT Q1 2022 : Strong Orviglance support from healthcare professionals
AQ
05/11Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Ascelia Pharma's Food Effect Study shows that Orviglance image enhancement of the liver..
AQ
05/10Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is N..
CI
05/05Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022
AQ
05/05Ascelia Pharma AB Announces Resignation of Bo Jesper Hansen as Board Member
CI
04/11Ascelia Pharma publishes Annual Report for 2021
AQ
04/05Notice of annual general meeting in ascelia pharma ab
AQ
04/01CFO Kristian Borbos to leave Ascelia Pharma
AQ
More news
Financials
Sales 2022 - - -
Net income 2022 -155 M -15,6 M -15,6 M
Net cash 2022 104 M 10,4 M 10,4 M
P/E ratio 2022 -4,57x
Yield 2022 -
Capitalization 692 M 69,4 M 69,4 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 21
Free-Float 83,7%
Chart ASCELIA PHARMA AB (PUBL)
Duration : Period :
Ascelia Pharma AB (publ) Technical Analysis Chart | ACE | SE0010573113 | MarketScreener
Technical analysis trends ASCELIA PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 20,55 SEK
Average target price 61,50 SEK
Spread / Average Target 199%
EPS Revisions
Managers and Directors
Magnus Olafsson Corfitzen Chief Executive Officer
Kristian Borbos Chief Financial Officer
Peter James Arthur Benson Chairman
Carl Bjartmar Chief Medical Officer
Bo Jesper Hansen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ASCELIA PHARMA AB (PUBL)-31.16%69
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567